Drugs / Ryplazim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03642691 | — | hypoplasminogenemia | Prometic Biotherapeutics, Inc. | No longer available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ryplazim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03642691 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT03642691 ↗ |